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Background: Intraoperative detection of 18F-FDG-avid tissue sites during 18F-FDG-directed surgery can be very
challenging when utilizing gamma detection probes that rely on a fixed target-to-background (T/B) ratio
(ratiometric threshold) for determination of probe positivity. The purpose of our study was to evaluate the counting
efficiency and the success rate of in situ intraoperative detection of 18F-FDG-avid tissue sites (using the three-sigma
statistical threshold criteria method and the ratiometric threshold criteria method) for three different gamma
detection probe systems.
Methods: Of 58 patients undergoing 18F-FDG-directed surgery for known or suspected malignancy using gamma
detection probes, we identified nine 18F-FDG-avid tissue sites (from amongst seven patients) that were seen on
same-day preoperative diagnostic PET/CT imaging, and for which each 18F-FDG-avid tissue site underwent
attempted in situ intraoperative detection concurrently using three gamma detection probe systems (K-alpha
probe, and two commercially-available PET-probe systems), and then were subsequently surgical excised.
Results: The mean relative probe counting efficiency ratio was 6.9 (± 4.4, range 2.2–15.4) for the K-alpha probe, as
compared to 1.5 (± 0.3, range 1.0–2.1) and 1.0 (± 0, range 1.0–1.0), respectively, for two commercially-available
PET-probe systems (P < 0.001). Successful in situ intraoperative detection of 18F-FDG-avid tissue sites was more
frequently accomplished with each of the three gamma detection probes tested by using the three-sigma statistical
threshold criteria method than by using the ratiometric threshold criteria method, specifically with the three-sigma
statistical threshold criteria method being significantly better than the ratiometric threshold criteria method for
determining probe positivity for the K-alpha probe (P = 0.05).
Conclusions: Our results suggest that the improved probe counting efficiency of the K-alpha probe design
used in conjunction with the three-sigma statistical threshold criteria method can allow for improved detection of
18F-FDG-avid tissue sites when a low in situ T/B ratio is encountered.
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Intraoperative gamma probe detection of various radioiso-
topes during radioguided surgery has become common-
place and is an established discipline within the practice of
surgery [1]. Along these lines, 18F-fluorodeoxyglucose
(18F-FDG), which is widely used for diagnostic positron
emission tomography (PET) imaging for a variety of solid
malignancies, has recently become the object of increased
investigations into its utility for the identification of 18F-
FDG-avid tissue sites during radioguided surgery [2-12]. In
this specific regard, it has become increasingly advanta-
geous to specifically design intraoperative radiation detec-
tion probes to directly or indirectly detect the resultant
511 KeV gamma emissions following positron annihilation
emanating from 18F-FDG-avid tissues. Nevertheless, most
gamma detection probes that are currently commercially
available have been designed for detecting radioisotopes of
gamma-ray energies much lower than 511 KeV. Such ra-
dioisotopes include: (1) 99mTc (140 and 142 KeV) that has
most commonly been used for sentinel lymph node biopsy
procedures and parathyroid surgery; (2) 111In (171 and 247
KeV) that has been used with octreotide to detect neuroen-
docrine tumors; (3) 123I (159 KeV) that has been used with
metaiodobenzylguanidine to detect neuroblastomas and
pheochromocytomas; and (4) 125I (35 KeV) that has been
used with anti-TAG-72 monoclonal antibodies and anti-
CEA monoclonal antibodies during radioimmunoguided
surgery [1].
The success of detecting and localizing 18F-FDG-avid
tissue sites during 18F-FDG-directed surgery is affected
by several factors, including: (1) the counting efficiency
of the detection probe used; and (2) the target-to-back-
ground (T/B) ratio of the radioactive emissions of 18F-
FDG. Various authors have examined the role played by
the T/B ratio for correctly identifying 18F-FDG-avid tis-
sue sites for PET imaging [13] and during 18F-FDG-di-
rected surgery [14-20]. The finding of a low T/B ratio of
18F-FDG is multifactorial, and can be influenced by fac-
tors such as the paucity of tumor vascularization, the
co-existence of large areas of tumor necrosis, the exist-
ence of an intrinsic low metabolic rate for some tumors,
and the close proximity of tumor to areas of elevated
physiologic 18F-FDG uptake or accumulation [1,16-20].
Gulec et al. [16-18] has suggested that a minimum in
situ T/B ratio of 1.5-to-1.0 for 18F-FDG is necessary, in
order “for the operating surgeon to be comfortable that
the difference between tumor and normal tissue are sig-
nificant” during 18F-FDG-directed surgery. However, it
has been our own experience that the observed in situ
T/B ratio seen during 18F-FDG-directed surgery is com-
monly less than 1.5-to-1.0, and is highly dependent upon
the specific detection probe used. Therefore, the in situ
intraoperative detection and localization of 18F-FDG-
avid tissue sites during 18F-FDG-directed surgery can bevery challenging when utilizing standard gamma detec-
tion probes and PET probes that rely solely on a fixed
T/B ratio (i.e., ratiometric threshold) as the threshold for
probe positivity for the identification of 18F-FDG-avid
tissue sites.
In this regard, it is our contention that improved in
situ intraoperative detection of 18F-FDG-avid tissue sites
with a gamma detection probe system can be attained by
taking advantage of the increased probe counting effi-
ciency offered by the K-alpha probe design [21] and by
utilizing a variance-based statistical analysis schema [22]
with the three-sigma criteria [23,24].
A variance-based statistical analysis schema was previ-
ously described by Currie for qualitative detection and
quantitative determination in radiochemistry [22]. By ap-
plying hypothesis testing, Currie reduced the threshold
for a significant difference between background radiation
and target radiation to a variance-based statistical model.
Such hypothesis testing and statistical modeling has be-
come commonplace in the analysis of medical data, in-
cluding medical imaging [25,26]. The application of
variance-based modeling to the determination of the
threshold for gamma detection probe positivity, in the
form of the three-sigma criteria for gamma detection
probe positivity, was popularized by Thurston [23,24]
and has since then been well validated in radioimmunoguided
surgery involving 125I- labeled anti-TAG-72 monoclonal
antibodies [24,27-31]. The three-sigma criteria defines a
tissue as being probe positive when the count rate in that
tissue exceeds three standard deviations above the count
rate detected with normal adjacent background tissue
[23,24,27-31].
An example of a gamma detection probe that can
greatly benefit from the three-sigma statistical threshold
criteria is the K-alpha probe [21]. The K-alpha probe de-
sign, which was also elucidated by Thurston in 2007, uti-
lizes the concept of detecting secondary, lower energy
gamma emissions (K-alpha x-ray fluorescence) that re-
sult when a thin metal foil plate (typically lead) is placed
between a cadmium-zinc-telluride crystal and a source
of gamma emissions, such as 18F-FDG [21]. It is our
contention that when concurrently utilized, the K-alpha
probe design and the three-sigma criteria can improve
the intraoperative detection of 18F-FDG-avid tissue sites,
even at very low T/B ratios for 18F-FDG, and would rep-
resent a methodology that is superior to a fixed T/B ra-
tio (i.e., ratiometric threshold) methodology used by
other gamma detection probe systems for detection of
18F-FDG-avid tissue sites.
In the current report, we evaluated the probe counting
efficiency and the success rate of in situ intraoperative
detection of 18F-FDG-avid tissue sites (using the three-
sigma statistical threshold criteria method and the
ratiometric threshold criteria method) that were assessed
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(consisting of the K-alpha probe system and two
commercially-available PET-probe systems) during 18F-
FDG-directed surgery.
Methods
All data analyzed in this manuscript were obtained from
the master database of an institutional review board
(IRB)-approved, prospective, pilot study protocol for
multimodal imaging and detection performed during
18F-FDG-directed surgery for known or suspected
malignancy at the Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute of The Ohio State
University Wexner Medical Center that was previously
approved by the Cancer IRB of the Office of Responsible
Research Practices of The Ohio State University.
From a total of 65 patients who gave informed consent
to participate in the IRB-approved, prospective, pilot
study protocol, a total of 60 patients were taken to the
operating room, and of which 58 patients underwent
18F-FDG-directed surgery for known or suspected malig-
nancy using gamma detection probes. Of those 58 pa-
tients undergoing 18F-FDG-directed surgery for known
or suspected malignancy using gamma detection probes,
we identified all cases in which 18F-FDG-avid tissue sites
were identified on same-day preoperative diagnostic
PET/CT imaging, and for which each of these 18F-FDG-
avid tissue sites underwent attempted in situ intraoperative
detection (based upon determination of the in situ counts
per second measurements recorded during 18F-FDG-di-
rected surgery) concurrently using three separate
gamma detection probe systems, and then were subse-
quently surgical excised. The first system was the K-alpha
probe system [21]. The two other systems represented
commercially-available PET-probe systems that were
designed specifically to directly or indirectly detect result-
ant 511 KeV gamma emissions following positron annihila-
tion emanating from 18F-FDG-avid tissue sites. These two
commercially-available PET-probe systems were the RMD
Navigator™ Gamma-PET™ probe system (RMD PET
probe; Dynasil Corporation, Watertown, MA) and the
NeoprobeW neo2000W GDS PET probe system (Neoprobe
PET probe; Devicor Medical Products, Incorporated,
Cincinnati, OH). All three gamma detection probe systems
had to be used concurrently in each case for attempted
in situ intraoperative detection in order for any particular
case to qualify for inclusion in the current analyses.
In each instance, a count rate (i.e., counts per second)
was taken from an area selected for the measurement of
background tissue count rate and from the area of pre-
sumed 18F-FDG-avid tissue selected for the measure-
ment of target tissue count rate. An area of presumed
normal tissue within a region adjacent to the area of the
target tissue was selected for the measurement ofbackground tissue count rate. Three separate recorded
values were used to generate each averaged target tissue
count rate measurement determined for each area of
presumed 18F-FDG-avid tissue. All values used for the
averaged count rate measurements were reported as av-
eraged counts per second. All of the averaged target tis-
sue count rate measurements that are reported in this
paper represent measurements taken on an area of pre-
sumed 18F-FDG-avid tissue before it was surgically ex-
cised (i.e., in situ measurements). None of the averaged
target tissue count rate measurements that are reported
in this paper represent measurements taken on an area
of presumed 18F-FDG-avid tissue after it was surgically
excised (i.e., ex situ measurements).
The counting efficiency [32] of each of the three
gamma detection probe systems was calculated for each
18F-FDG-avid tissue site identified during in situ
intraoperative detection. The probe counting efficiency
was defined as a relative probe counting efficiency ratio
for each of the individual three gamma detection probe
systems, consisting of the ratio of the averaged target
tissue count rate for each 18F-FDG-avid tissue site using
each of the individual three gamma detection probe
systems as compared to the averaged target tissue count
rate of the gamma detection probe system with
the lowest averaged target tissue count rate for each 18F-
FDG-avid tissue site. Thus, the relative probe counting
efficiency ratio for the gamma detection probe system
with the lowest averaged target tissue count rate will re-
sultantly be reported as 1.0.
A calculated fixed T/B ratio was calculated for each
target tissue as the ratio of the averaged target tissue
count rate to the background tissue count rate. A calcu-
lated three-sigma criteria count rate was calculated for
each target tissue by the methodology popularized of
Thurston [23,24], based upon taking the standard devi-
ation derived from the normal background tissue count
rate and multiplying that standard deviation by a factor
of three and then adding that number to the normal
background tissue count rate. For the calculated fixed T/
B ratio method (i.e., ratiometric threshold criteria
method), a ratiometric threshold of 1.5-to-1.0 or greater
was set as the ratiometric threshold criteria of probe
positivity. For the calculated three-sigma criteria count
rate method, three-sigma statistical threshold of probe
positivity was met when the calculated three-sigma
criteria count rate for the target tissue was exceeded
by the actual target tissue count rate. The deter-
mination of probe positivity for successful in situ
intraoperative detection of 18F-FDG-avid tissue sites
by each of the three gamma detection probe systems
was then compared both by the ratiometric thresh-
old criteria method and by the three-sigma statis-
tical threshold criteria method.
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software program IBM SPSSW 19 for WindowsW (SPSS,
Inc., Chicago, Illinois) was used for the data analysis. All
mean value comparisons were made by one-way analysis
of variance (ANOVA). All categorical variable compari-
sons were made using 2 × 2 or 2 × 3 contingency tables
that were analyzed by either the Pearson chi-square test
or the Fisher exact test, when appropriate. Categorical
variable comparisons were made for probe type as a
function of threshold criteria and for threshold criteria
as a function of probe type. P-values determined to be
0.05 or less were considered to be statistically significant.
All reported categorical variable comparisons P-values
were two-sided.
Results
Of those 58 patients undergoing 18F-FDG-directed sur-
gery for known or suspected malignancy using gamma
detection probes, we identified seven patients (four
Caucasian males, two Caucasian females, and one
African-American female) who underwent same-day
preoperative diagnostic PET/CT imaging and in whom
all three previously described gamma detection probe
systems were then concurrently utilized for attempted
in situ intraoperative identification of 18F-FDG-avid tis-
sue sites between the dates of March 3, 2009 and March
19, 2009. These seven patients had a mean age of 57
(± 12, range 41–80) years, a mean body weight of 79.8
(± 16.8, range 59.9–102.1) kilograms or 176 (± 37, range
132–225) pounds, and a mean same-day pre-scanning
blood sugar of 99 (± 21, range 78–137) milligrams per
deciliter. The mean 18F-FDG injection dose was 540
(± 51, range 433–587) MBq or 14.6 (± 1.4, range 11.7–
15.9) millicuries.
Within this group of seven patients, a total of nine
separate 18F-FDG-avid tissue sites, which were identified
on same-day preoperative diagnostic PET/CT imaging,
were intraoperatively assessed in situ with all three
gamma detection probe systems, and were subsequently
surgical excised. Additionally, in one of the seven pa-
tients, there were four intraoperative clinically suspicious
sites (i.e., intraoperative clinically palpable sites) withinTable 1 Mean value of various count rate variables, relative p
18F-FDG-avid tissue sites tested by the three different gamm
Mean value of each variable K-alpha probe
Averaged target tissue count rate
(counts per second)
960 (± 907, range 80–2
Background tissue count rate in adjacent area
of presumed normal tissue (counts per second)
755 (± 858, range 32–2
Relative probe counting efficiency ratio 6.9 (± 4.4, range 2.2–15
Calculated fixed T/B ratio 1.6 (± 0.6, range 1.1–2.
Calculated three-sigma criteria count
rate (counts per second)
827 (± 901, range 49–2the surgical field that were not 18F-FDG-avid on pre-
operative same-day diagnostic PET/CT imaging, but
were intraoperatively assessed in situ with all three
gamma detection probe systems and were subsequently
surgical excised.
The nine separate 18F-FDG-avid tissue sites had a
mean SUVmax of 8.6 (± 3.8, range 1.9–13.4) on same-
day preoperative diagnostic PET/CT imaging. The mean
time from 18F-FDG injection to same-day preoperative
diagnostic PET/CT imaging in the seven patients evalu-
ated was 94 (± 38, range 66–179) minutes, with only
one patient exceeding mean time of 94 minutes from
18F-FDG injection to same-day preoperative diagnostic
PET/CT imaging. The mean time from 18F-FDG injec-
tion to the time of the start of surgery in the seven pa-
tients evaluated was 219 (± 61, range 168–305) minutes.
The mean time from 18F-FDG injection to the time of
attempted in situ intraoperative gamma probe detection
in the seven patients evaluated was 295 (± 87, range
187–409) minutes.
In Table 1, the mean value of various count rate vari-
ables, relative probe counting efficiency ratio, and T/B
ratio for the nine 18F-FDG-avid tissue sites tested by the
three different gamma detection probe systems are
shown.
The mean of the averaged target tissue count rate for
the nine 18F-FDG-avid tissue sites was 960 (± 907, range
80–2509) counts per second using the K-alpha probe
system, 203 (± 153, range 45–446) counts per second
using the RMD PET probe system, and 150 (± 121,
range 32–322) counts per second using the Neoprobe
PET probe system (P = 0.006).
The mean of the background tissue count rate in an
area of presumed normal tissue within a region adjacent
to the nine 18F-FDG-avid tissue sites was 755 (± 858,
range 32–2257) counts per second using the K-alpha
probe system, 133 (± 104, range 37–344) counts per sec-
ond using the RMD PET probe system, and 71 (± 65,
range 18–197) counts per second using the Neoprobe
PET probe system (P = 0.014).
The probe counting efficiency was assessed for all
three gamma detection probe systems. The meanrobe counting efficiency ratio, and T/B ratio for the nine
a detection probe systems
RMD PET probe Neoprobe PET probe P-value
509) 203 (± 153, range 45–446) 150 (± 121, range 32–322) 0.006
257) 133 (± 104, range 37–344) 71 (± 65, range 18–197) 0.014
.4) 1.5 (± 0.3, range 1.0–2.1) 1.0 (± 0, range 1.0–1.0) <0.001
5) 1.6 (± 0.5, range 1.2–2.4) 2.3 (± 1.0, range 1.4–4.2) 0.073
400) 165 (± 117, range 55–400) 94 (± 76, range 31–239) 0.012
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range 2.2–15.4) for the K-alpha probe system, was 1.5
(± 0.3, range 1.0–2.1) for the RMD PET probe system,
and was 1.0 (± 0, range 1.0–1.0) for the Neoprobe PET
probe system (P < 0.001).
The mean of the calculated fixed T/B ratio for the nine
18F-FDG-avid tissue sites was 1.6 (± 0.6, range 1.1–2.5)
for the K-alpha probe system, 1.6 (± 0.5, range 1.2–2.4)
for the RMD PET probe system, and 2.3 (± 1.0, range
1.4–4.2) for the Neoprobe PET probe system (P = 0.073).
The mean of the calculated three-sigma criteria count
rate for the nine 18F-FDG-avid tissue sites was 827
(± 901, range 49–2400) counts per second for the K-
alpha probe system, 165 (± 117, range 55–400) counts
per second for the RMD PET probe system, and 94
(± 76, range 31–239) counts per second for the
Neoprobe PET probe system (P = 0.012).
The detection success rate for probe positivity for the
nine separate 18F-FDG-avid tissue sites by the ratiometric
threshold criteria method and by the three-sigma statis-
tical threshold criteria method at the time of attempted in
situ intraoperative detection was assessed for all three
gamma detection probe systems. The K-alpha probe sys-
tem detection success rate for probe positivity was in 3/9
cases (33%) by the ratiometric threshold criteria method
and in 8/9 cases (89%) by the three-sigma statistical
threshold criteria method. The RMD PET probe system
detection success rate for probe positivity was in 3/9 cases
(33%) by the ratiometric threshold criteria method and in
4/9 cases (44%) by the three-sigma statistical threshold
criteria method. The Neoprobe PET probe system detec-
tion success rate for probe positivity was in 7/9 cases
(78%) by the ratiometric threshold criteria method and in
8/9 cases (89%) by the three-sigma statistical threshold
criteria method. Therefore, with each of the three gamma
detection probe systems tested, successful in situ
intraoperative detection of 18FDG-avid tissue sites was
more frequently accomplished by using the three-sigma
statistical threshold criteria method than by using the
ratiometric threshold criteria method. While the overall
categorical variable comparison of the three gamma detec-
tion probe systems utilized as a function of the specific
threshold criteria used was not found to be statistically
significant (P = 0.094), the individual categorical variable
comparison of the K-alpha probe as a function of the
specific threshold criteria used demonstrated that the
three-sigma statistical threshold criteria method was sig-
nificantly better than the ratiometric threshold criteria
method for determining probe positivity for the K-alpha
probe (P = 0.050). All other categorical variable compari-
sons for probe type as a function of threshold criteria and
for threshold criteria as a function of probe type were
found not to be statistically significant, with the lack of
significant differences in these categorical variablecomparisons most realistically attributable to the small
number of cases available for each of these resultant 2 × 2
and 2 × 3 contingency table analyses.
The previously mentioned four intraoperative clinically
suspicious sites that were identified in one of the seven
patients (that were not 18F-FDG-avid on preoperative
same-day diagnostic PET/CT imaging, but were intraop-
eratively assessed in situ with all three gamma detection
probe systems and were subsequently surgical excised)
were not determined to be probe positive by the
ratiometric threshold criteria method or by the three-
sigma statistical threshold criteria method at the time of
attempted in situ intraoperative detection by any of the
three gamma detection probe systems.
All nine separate 18F-FDG-avid tissue sites (which were
identified on same-day preoperative diagnostic PET/CT
imaging, and which were intraoperatively assessed in situ
with all three gamma detection probe systems and subse-
quently surgical excised), were visualized as 18F-FDG-avid
tissue sites on same-day perioperative ex situ specimen
PET/CT imaging. The mean time from 18F-FDG injection
to same-day perioperative specimen PET/CT imaging for
the nine separate 18F-FDG-avid tissue specimens evalu-
ated was 488 (± 130, range 340–661) minutes. None of
the four intraoperative clinically suspicious sites that were
identified in one of the seven patients (that were not 18F-
FDG-avid on preoperative same-day diagnostic PET/CT
imaging, but were intraoperatively assessed in situ with all
three gamma detection probe systems and were subse-
quently surgical excised) were visualized as potential 18F-
FDG-avid tissue sites on same-day perioperative ex situ
specimen PET/CT imaging.
Final histopathologic evaluation of the nine separate
18F-FDG-avid tissue sites revealed squamous cell carcin-
oma of the head and neck region in five 18F-FDG-avid tis-
sue sites, as well one site containing invasive ductal
carcinoma of the breast, one site containing non-small cell
carcinoma of the lung, one site containing malignant mel-
anoma, and one site containing eccrine porocarcinoma.
Final histopathologic evaluation of the four intraoperative
clinically suspicious sites identified in one of the seven
patients (that were not 18F-FDG-avid on preoperative
same-day diagnostic PET/CT imaging and were not intra-
operatively detected in situ with any of the three gamma
detection probe systems and were subsequently surgical
excised and were not visualized as potential 18F-FDG-avid
tissue sites on same-day perioperative ex situ specimen
PET/CT imaging) showed benign lymphoid tissue only.
Discussion
It is our observation that in situ T/B ratios for 18F-FDG-
avid tissue sites detected intraoperatively are often less
than 1.5-to-1.0, making localization of such 18F-FDG-
avid tissue sites very challenging when utilizing standard
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on a fixed T/B ratio (ratiometric threshold criteria
method) as the threshold for probe positivity. Therefore,
an optimized gamma detection probe design that allows
for the in situ intraoperative detection and localization
of 18F-FDG-avid tissue sites having an in situ T/B ratio
of less than 1.5-to-1.0 is essential to performing success-
ful 18F-FDG-directed surgery.
In the current report, we evaluated the probe counting
efficiency and the success rate of in situ intraoperative
detection of 18F-FDG-avid tissue sites (using the three-
sigma statistical threshold criteria method and the
ratiometric threshold criteria method) for three gamma
detection probe systems tested during 18F-FDG-directed
surgery. We found that the mean relative probe counting
efficiency was significantly better (P < 0.001) for the K-
alpha probe system than for the two commercially-
available PET-probe systems. Likewise, we found that
successful in situ intraoperative detection of 18F-FDG-
avid tissue sites was more frequently accomplished by
using the three-sigma statistical threshold criteria
method than by using the ratiometric threshold criteria
method with each of the three gamma detection probe
systems tested. In that regard, as based upon categorical
variable comparison of the K-alpha probe as a function
of the specific threshold criteria used, we specifically
found that the three-sigma statistical threshold criteria
method was significantly better than the ratiometric
threshold criteria method for determining probe positiv-
ity for the K-alpha probe (P = 0.050). Yet, there was a
general lack of significant differences in our analyses of
all other individual categorical variable comparisons be-
tween probe type as a function of threshold criteria and
between threshold criteria as a function of probe type. It
is our contention this finding is most realistically attrib-
utable the small sample size (n = 9) that was available for
the 2 × 2 and 2 × 3 contingency table analyses.
When applying commercially-available PET probe sys-
tems for the detection of 18F-FDG-avid tissue sites, the
probe counting efficiency falls off rapidly with increasing
gamma energy levels [19,20]. The intrinsic counting effi-
ciency (i.e. the efficiency taking collimation and probe
housing into account) of such commercially-available
PET probe systems is less than 2% at a gamma energy
level of 511 KeV [19,20]. The physical size and weight of
a typical PET probe is primarily a function of the side
shielding that is required to block background radiation,
to limit the field of view, and to collimate the head of
the probe, with the intention to limit the area of the tis-
sue contributing to the probe count rate and to provide
better spatial resolution between tissues of differing
radioactivity levels [1]. Attempts at improving PET
probe design by further increasing collimation and by
creating crystal geometry of sufficient diameter andthickness to capture a higher percentage of 511 KeV
gamma emissions would result in a PET probe construct
that would be prohibitively large in physical size, heavy
in weight, and expensive [1,21]. These factors represent
significant barriers to the clinical application of currently
commercially-available PET probe systems for the detec-
tion of 18F-FDG-avid tissue sites.
The use of collimation in PET probe design has very
divergent effects on the probe counting efficiency versus
the resultant T/B ratio observed, with collimation redu-
cing probe counting efficiency at 18F-FDG-avid tissue
sites and increasing the T/B ratio observed at 18F-FDG-
avid tissue sites [1,19,20]. The effects of collimation are
evident in both the determination of the probe counting
efficiency and in the T/B ratio observed for the three
gamma detection probe systems we examined, with the
K-alpha probe having significantly better mean relative
probe counting efficiency ratio as compared to the RMD
PET probe system or the Neoprobe PET probe (6.9 for
the K-alpha probe versus 1.5 for the RMD PET probe
and 1.0 for the Neoprobe PET probe; P < 0.001) and with
the Neoprobe PET probe having nearly-significantly im-
provement in the mean T/B ratio observed as compared
to the K-alpha probe or the RMD PET probe (2.3 for the
Neoprobe PET probe versus 1.6 for the K-alpha probe
and 1.6 for the RMD PET probe system; P = 0.073).
Therefore, the Neoprobe PET probe performed the best
with the ratiometric threshold criteria method because it
was specifically designed to maximize the T/B ratio
through the use of increased collimation for attempting
to directly count the 511 KeV gamma photon emissions.
Yet, commercially-available PET probe systems, like the
Neoprobe PET probe, which utilize increased collima-
tion and have a resultantly low probe counting efficiency
cannot fully take advantage of the three-sigma statistical
threshold criteria method.
However, the K-alpha probe design [21], which lacks
collimation, has a significantly higher probe counting ef-
ficiency, and has a decrease in the T/B ratio, can specif-
ically benefit from the use of the three-sigma statistical
threshold criteria method. It is our contention that the
higher probe counting efficiency of the K-alpha probe
design allowed for successful in situ intraoperative de-
tection of 18F-FDG-avid tissue sites with lower T/B ra-
tios, even down to a T/B ratio as low as 1.1-to-1.0. This
is the end result of the fact that the K-alpha probe [21]
does not directly count the 511 KeV gamma photon
emissions, and instead counts the secondary, lower en-
ergy gamma emissions (K-alpha x-ray fluorescence) from
a thin lead plate placed between the detection crystal
and the source of gamma emissions, producing a much
higher probe counting efficiency. Thus, its higher probe
counting efficiency and the direct counting of secondary,
lower energy gamma emissions by the K-alpha probe
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three-sigma statistical threshold criteria method. Further-
more, the K-alpha probe can be designed to be sig-
nificantly smaller and lighter in weight than any
commercially-available PET probe system, since the detec-
tion crystal can be made relatively thin and can be housed
within a detection probe head with little or no needed col-
limation [21]. This resultant K-alpha design opens up the
possibilities for the production of a commercially-available
PET probe system that can be easily adapted for use in
laparoscopic and robotic surgeries.Conclusions
Probe counting efficiency was significantly better for the K-
alpha probe system than for the two commercially-available
PET-probe systems. Successful in situ intraoperative detec-
tion of 18F-FDG-avid tissue sites was more frequently ac-
complished with each of the three gamma detection probe
systems tested by using the three-sigma statistical threshold
criteria method than by using the ratiometric threshold cri-
teria method, specifically with the three-sigma statistical
threshold criteria method being significantly better than the
ratiometric threshold criteria method for determining
probe positivity for the K-alpha probe. Our results suggest
that the improved probe counting efficiency of the K-alpha
probe design used in conjunction with the three-sigma stat-
istical threshold criteria method can allow for improved de-
tection of 18F-FDG-avid tissue sites when a low in situ T/B
ratio is encountered. Further research and development
are needed to more clearly understand these findings and
to optimize gamma detection probe design for the
intraoperative detection of 18F-FDG-avid tissue sites during
18F-FDG-directed surgery.
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